gefitinib has been researched along with Pulmonary Fibrosis in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (58.82) | 29.6817 |
| 2010's | 5 (29.41) | 24.3611 |
| 2020's | 2 (11.76) | 2.80 |
| Authors | Studies |
|---|---|
| Bai, Y; Chen, L; Chu, P; Han, X; Li, L; Li, Y; Ma, X; Qi, Y; Sun, H; Wang, C; Zhang, B; Zhang, Y | 1 |
| Cao, Z; Chen, Y; Guo, W; Hu, H; Li, B; Liu, J; Pang, J; Song, M; Song, X; Wang, C; Wang, J; Wang, M; Xing, Y; Yang, H; Yang, J; Yang, P; Zhang, T; Zhang, Z | 1 |
| Chen, H; Han, R; He, Y; Huang, W; Li, K; Li, L; Lin, C; Lu, C; Sun, F; Wang, Y; Zhang, K | 1 |
| Azuma, A; Hagiwara, K; Kudoh, S | 1 |
| Ishihara, S; Minato, K; Mogi, A; Naito, Y; Saito, R; Shitara, Y; Suga, T; Takise, A; Tsuchiya, S; Yamabe, K | 1 |
| Katayama, H; Kishino, D; Kiura, K; Kuyama, S; Ohashi, K; Okada, T; Sato, K; Takigawa, N; Tanimoto, M | 1 |
| Chen, LA; Liang, ZX; Sun, JP; Tian, Q; Wang, P; Xu, SF; Yang, Z | 1 |
| Cai, L; Huang, WJ; Li, L; Li, WF; Yuan, WF | 1 |
| Azuma, A; Hoshino, T; Mizushima, T; Namba, T; Tanaka, K | 1 |
| Aono, Y; Hanibuchi, M; Kakiuchi, S; Kishi, J; Miyake, K; Nishioka, Y; Sone, S; Suzuka, C; Tani, K; Tezuka, T; Toyoda, Y; Yuasa, S | 1 |
| Ouchi, Y; Teramoto, S; Yamamoto, H | 1 |
| Aoshiba, K; Nagai, A; Suzuki, H; Yokohori, N | 1 |
| Choe, JK; Cogswell, J; Kasimis, B; Nagaria, NC | 1 |
| Le Chevalier, T; Tsuboi, M | 1 |
| Fujimoto, S; Fukuda, T; Ishii, Y | 1 |
| Kishi, K; Nakata, K; Yoshimura, K | 1 |
| Davidson, C; Hardie, WD; Ikegami, M; Korfhagen, TR; Le Cras, TD; Leikauf, GD; Prestridge, A; Whitsett, JA | 1 |
17 other study(ies) available for gefitinib and Pulmonary Fibrosis
| Article | Year |
|---|---|
Synthesis and biological evaluation of selenogefitinib for reducing bleomycin-induced pulmonary fibrosis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Bleomycin; Dose-Response Relationship, Drug; Mice; Molecular Structure; Pulmonary Fibrosis; Structure-Activity Relationship | 2021 |
Gefitinib and fostamatinib target EGFR and SYK to attenuate silicosis: a multi-omics study with drug exploration.
Topics: Aminopyridines; Animals; ErbB Receptors; Gefitinib; Inflammation; Mice; Morpholines; Pulmonary Fibrosis; Pyridines; Pyrimidines; Silicosis | 2022 |
Metformin attenuates gefitinib-induced exacerbation of pulmonary fibrosis by inhibition of TGF-β signaling pathway.
Topics: Animals; Antineoplastic Agents; Bleomycin; Blotting, Western; Epithelial-Mesenchymal Transition; Flow Cytometry; Gefitinib; Humans; Immunohistochemistry; Lung Diseases, Interstitial; Male; Metformin; Pulmonary Fibrosis; Quinazolines; Rats; Rats, Sprague-Dawley; Signal Transduction; Transforming Growth Factor beta | 2015 |
Basis of acute exacerbation of idiopathic pulmonary fibrosis in Japanese patients.
Topics: Acute Disease; Asian People; Gefitinib; Genetic Predisposition to Disease; Humans; Japan; Protein Kinase Inhibitors; Pulmonary Fibrosis; Quinazolines | 2008 |
Impact of preexisting pulmonary fibrosis detected on chest radiograph and CT on the development of gefitinib-related interstitial lung disease.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Protein Kinase Inhibitors; Pulmonary Fibrosis; Quinazolines; Radiography, Thoracic; Retrospective Studies; Risk Factors; Survival Rate; Tomography, X-Ray Computed | 2008 |
Effect of gefitinib on N-nitrosamine-4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induced lung tumorigenesis in A/J mice.
Topics: Animals; Antineoplastic Agents; Carcinogens, Environmental; Cell Growth Processes; Cell Line, Tumor; Cell Transformation, Neoplastic; ErbB Receptors; Female; Gefitinib; Lung; Lung Neoplasms; Mice; Mice, Inbred Strains; Neoplasms, Experimental; Nitrosamines; Pulmonary Fibrosis; Quinazolines; Smoking; Tumor Burden | 2009 |
Gefitinib attenuates murine pulmonary fibrosis induced by bleomycin.
Topics: Animals; Bleomycin; Blotting, Western; Collagen Type I; Collagen Type III; ErbB Receptors; Gefitinib; Male; Mice; Mice, Inbred C57BL; Protein Kinase Inhibitors; Pulmonary Fibrosis; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction | 2010 |
[Gefitinib inhibits α-smooth muscle actin expression in mice with bleomycin-induced lung fibrosis].
Topics: Actins; Animals; Bleomycin; ErbB Receptors; Gefitinib; Lung; Male; Mice; Mice, Inbred BALB C; Pulmonary Fibrosis; Quinazolines; RNA, Messenger | 2010 |
Suppression of expression of heat shock protein 70 by gefitinib and its contribution to pulmonary fibrosis.
Topics: Animals; Cell Line, Tumor; ErbB Receptors; Gefitinib; HSP70 Heat-Shock Proteins; Humans; Immunoblotting; Lung Diseases, Interstitial; Mice; Mice, Transgenic; MicroRNAs; Protein Kinase Inhibitors; Pulmonary Fibrosis; Quinazolines; Real-Time Polymerase Chain Reaction | 2011 |
Epidermal growth factor receptor-tyrosine kinase inhibitor (gefitinib) augments pneumonitis, but attenuates lung fibrosis in response to radiation injury in rats.
Topics: Animals; Disease Models, Animal; ErbB Receptors; Gefitinib; Male; Protein Kinase Inhibitors; Pulmonary Fibrosis; Quinazolines; Radiation Pneumonitis; Rats; Rats, Wistar | 2012 |
Clinical efficacy and toxicity of gefitinib in patients with lung cancer.
Topics: Antineoplastic Agents; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Pulmonary Fibrosis; Quinazolines; Radiography | 2003 |
Epidermal growth factor receptor tyrosine kinase inhibition augments a murine model of pulmonary fibrosis.
Topics: Animals; Bleomycin; Cell Division; Disease Models, Animal; ErbB Receptors; Gefitinib; Male; Mice; Mice, Inbred ICR; Phosphorylation; Pulmonary Fibrosis; Quinazolines | 2003 |
Side effects and good effects from new chemotherapeutic agents. Case 1. Gefitinib-induced interstitial fibrosis.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cough; Dyspnea; Fatal Outcome; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Pulmonary Fibrosis; Quinazolines | 2005 |
Interstitial lung disease in patients with non-small-cell lung cancer treated with epidermal growth factor receptor inhibitors.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Incidence; Japan; Lung Neoplasms; Male; Protein Kinase Inhibitors; Pulmonary Fibrosis; Quinazolines; Risk Factors | 2006 |
Gefitinib prevents bleomycin-induced lung fibrosis in mice.
Topics: Animals; Bleomycin; Cell Culture Techniques; Cell Proliferation; Disease Models, Animal; Dose-Response Relationship, Drug; Fibroblasts; Gefitinib; Humans; Male; Mice; Mice, Inbred C57BL; Protein Kinase Inhibitors; Pulmonary Fibrosis; Quinazolines; Tyrphostins | 2006 |
Efficacy of gefitinib in a patient with lung cancer associated with idiopathic pulmonary fibrosis.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Protein Kinase Inhibitors; Pulmonary Fibrosis; Quinazolines | 2006 |
EGF receptor tyrosine kinase inhibitors diminish transforming growth factor-alpha-induced pulmonary fibrosis.
Topics: Animals; Bronchoalveolar Lavage Fluid; Doxycycline; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression; Humans; Mice; Pulmonary Fibrosis; Quinazolines; RNA, Messenger; Transforming Growth Factor alpha | 2008 |